CompletedPhase 2

Safety and Efficacy of FalateScan (Technetium Tc 99m EC20) in Patients With Known Suspected Recurrent or Metastatic Cancer From a Solid Tumor

40 participantsStarted 2003-08

Plain-language summary

The folate receptor is over-expressed on many types of cancer cells and new folate receptor targeted therapies are being developed to target cancer cells that over-express the folate receptor. As with other targeted therapies, it is important to develop diagnostic tests that will provide accurate information on folate receptor status and aid in selecting patients that may benefit from folate-targeted therapy.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patient must be 18 years of age or older.
✓. Patient must have known or strongly suspected recurrent or metastatic cancer from a solid tumor with at least one identifiable lesion \> 1.5 cm as diagnosed by conventional imaging.
✓. Patient must have adequate kidney function defined as serum creatinine of \< 1.5 X ULN.
✓. Patient must have adequate liver function defined as transaminases (SGOT and/or SGPT) may be up to 2.5 X ULN if alkaline phosphatase is \<ULN or alkaline phosphatase may be up to 2.5 X ULN if Transaminases are \< ULN. If alkaline phosphatase is outside of these parameters and is due to bone metastases verified by assessment of isoenzymes, then the subject is eligible.
✓. Patient must provide written informed consent prior to enrollment.

Exclusion criteria

✕. Patient is pregnant or breastfeeding.
✕. Patient is simultaneously participating in another investigational drug study, excluding the follow-up phase.
✕. Patient has received an investigational agent within 7 days prior to enrollment.
✕. Patient is unable to tolerate conditions for radionuclide imaging.
✕. Patient has been administered another radiopharmaceutical that would interfere with the assessment of Technetium Tc 99m EC20.

Trial details

NCT IDNCT01684098

SponsorEndocyte

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

View on ClinicalTrials.gov More Recurrent or Metastatic Cancer trials